Clinical Trials Logo

Sarcoma, Ewing clinical trials

View clinical trials related to Sarcoma, Ewing.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT04730349 Terminated - Neuroblastoma Clinical Trials

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

PIVOT IO 020
Start date: June 3, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children, adolescents and young adults with recurrent or treatment-resistant cancer.

NCT ID: NCT03604783 Terminated - Sarcoma Clinical Trials

Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors

Start date: December 26, 2018
Phase: Phase 1
Study type: Interventional

TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib. This is a Phase 1, open-label, dose-escalation, dose-expansion, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral TP-1287 in patients with advanced metastatic or progressive solid tumors who are refractory to, or intolerant of, established therapy known to provide clinical benefit for their condition.

NCT ID: NCT03514407 Terminated - Clinical trials for Relapsed Ewing Sarcoma

A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

Start date: June 27, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and preliminary antitumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy.

NCT ID: NCT03495921 Terminated - Neoplasms Clinical Trials

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

VITA
Start date: August 21, 2018
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial was to compare participants with first relapse or refractory Ewing's sarcoma when treated with investigational product (Vigil) in addition to the standard treatment of irinotecan and temozolomide compared to the standard treatment of irinotecan and temozolomide alone. The main question it aimed to answer is "Will participants who receive Vigil in addition to irinotecan and temozolomide have a prolonged time to progression and improved quality of life compared to the participants who receive irinotecan and temozolomide alone?".

NCT ID: NCT03458728 Terminated - Neuroblastoma Clinical Trials

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Start date: April 30, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.

NCT ID: NCT02657005 Terminated - Sarcoma, Ewing Clinical Trials

TK216 in Patients With Relapsed or Refractory Ewing Sarcoma

Start date: August 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Ewing sarcoma is characterized by genomic rearrangements resulting in over-expression of ets family transcription factors driving tumor progression. TK216 is designed to inhibit this effect by inhibiting downstream effects of the EWS-FLI1 transcription factor. This study is a first in human study of TK216 in subjects with Ewing sarcoma. The study is designed to establish initial safety and efficacy data in monotherapy and in combination with vincristine to assess the potential of TK216 for further development.

NCT ID: NCT02624388 Terminated - Lymphoma Clinical Trials

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

UVA-Gen001
Start date: August 2016
Phase: Phase 2
Study type: Interventional

Toxicities related to pediatric cancer treatment can lead to significant illness, organ damage, treatment delays, increased health care cost, and decrease in quality of life. Such toxicities are largely due to tissue damage sustained by chemotherapy, and strategies designed to limit such cellular damage to normal tissues may reduce therapy-related morbidity and mortality. In addition to their in vitro and in vivo anti-cancer effects, naturally occurring soy isoflavones have anti-inflammatory and anti-oxidant properties, and have been shown to reduce side effects of therapy in adult oncology clinical trials. This study will examine the effect of genistein, the major isoflavone component in soybeans and the most extensively studied of the soy isoflavones, on short-term side effects of myelosuppressive chemotherapy in pediatric cancer patients. Subjects will be randomized to receive either: a) 30 mg genistein daily throughout chemotherapy Cycles 1 and 2 and placebo during chemotherapy Cycles 3 and 4; or b) placebo daily during chemotherapy Cycles 1 and 2 and 30 mg genistein daily during chemotherapy Cycles 3 and 4. Investigators hypothesize that subjects will have fewer short-term therapy-related side effects during cycles of chemotherapy given in conjunction with genistein supplementation than cycles given with placebo.

NCT ID: NCT02581384 Terminated - Sarcoma Clinical Trials

Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors

Start date: January 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is studying stereotactic body radiotherapy (SBRT) as a possible treatment for lung relapse of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, Wilms tumor or other primary renal tumor (including clear cell and rhabdoid). SBRT is a form of targeted radiotherapy that can treat very small tumors using a few large doses.

NCT ID: NCT02536183 Terminated - Solid Tumors Clinical Trials

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors

Start date: October 2016
Phase: Phase 1
Study type: Interventional

This study is looking to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of lyso-thermosensitive liposomal doxorubicin (LTLD) administered in combination with MR-HIFU in children with relapsed/refractory solid tumors, which may include but are not limited to rhabdomyosarcoma and other soft tissue sarcomas, Ewing's sarcoma family of tumors, osteosarcoma, neuroblastoma, Wilms' tumor, hepatic tumors, and germ cell tumors.

NCT ID: NCT01882231 Terminated - Osteosarcoma Clinical Trials

Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma

Start date: March 2013
Phase: N/A
Study type: Interventional

The objective of these studies is to use changes in 3 Tesla MRI measurements of tumor protein content, cell density, and microvessel perfusion, obtained before and after a single cycle of NAC, to predict eventual tumor response observed at the conclusion of NAC, within patients with osteosarcoma or Ewing Sarcoma.